Celcuity, Inc. CELC

Celcuity secured landmark regulatory approval but faces high launch costs that could strain finances and slow commercialization. Landmark approval paired with costly launch creates major financial and strategic pressure on Celcuity's trajectory.

Celcuity submits sNDA to FDA for REVTORPYK (gedatolisib) in HR+/HER2- PIK3CA mutant locally advanced or metastatic breast cancer. sNDA submission for lead drug candidate marks key regulatory step with potential to enable approval and commercial revenue in breast cancer.

Celcuity (CELC) held its Q2 2026 earnings call to review quarterly financial results and business outlook. Earnings call supplies updated financial metrics and forward guidance that can materially shift investor views and share price.

Celcuity faces widening losses ahead of its first product launch, raising questions on whether the stock is a bargain at current levels. Widening losses before first launch could significantly affect investor sentiment and company valuation.

Celcuity (CELC) secures FDA approval for Revtopik while reporting a wider quarterly loss. FDA approval for Revtopik marks a major regulatory milestone likely to boost Celcuity's market position and future revenues.

Celcuity Inc received FDA approval and is advancing commercial launch plans following its Q2 2026 earnings call. FDA approval and commercial launch will redefine Celcuity's market position and growth trajectory.

Celcuity Inc. released its Q2 2026 earnings call summary with updates on financial results, operations, and outlook. Earnings call details provide performance metrics and guidance that can shift near-term investor sentiment.

Celcuity held Q2 earnings call discussing financial results, operational updates and future plans. Earnings highlights can influence near-term sentiment and valuations but rarely shift long-term company trajectory alone.

Celcuity Inc. released second quarter 2026 financial results along with a corporate update. Quarterly financial results and updates typically drive moderate stock movement and investor sentiment for the company.

Celcuity's REVTORPYK (gedatolisib) gains inclusion in NCCN guidelines for HR+/HER2- locally advanced or metastatic breast cancer after recent FDA approval. NCCN guideline inclusion expands market access and adoption for gedatolisib in key breast cancer indications.

Celcuity secured major FDA approval for its breast cancer diagnostic assay yet CELC shares fell 15% over the week on profit-taking, commercialization timeline concerns, and market rotation out of biotech names. FDA clearance directly unlocks commercial revenue potential and competitive positioning for Celcuity's core oncology platform.

Celcuity gains FDA approval for closely-watched breast cancer drug. FDA approval of key breast cancer drug enables Celcuity commercialization, revenue ramp, and fundamental competitive repositioning.

Celcuity gains FDA approval for REVTORPYK in advanced breast cancer and enters commercial stage. FDA approval launches commercial sales and transforms long-term market position.

Celcuity secured its first FDA approval yet its stock fell more than 10 percent immediately afterward. First FDA approval constitutes a major regulatory milestone that can materially shift company trajectory and investor views.

Celcuity secures first FDA approval for cancer drug, driving stock to best day in two months. First FDA cancer drug approval delivers transformative boost to Celcuity market position and long-term prospects.

Celcuity receives FDA approval for REVTORPYK™ (gedatolisib) to treat HR+/HER2-, PIK3CA wild-type locally advanced or metastatic breast cancer. FDA approval of gedatolisib opens major new revenue stream and fundamentally strengthens Celcuity's market position.

Celcuity raises $500 million through convertible notes, weighing dilution risks against funding for ongoing drug development. The $500 million convertible note offering supplies major new capital that can accelerate Celcuity's drug pipeline while carrying dilution risk for shareholders.

Celcuity expands Phase 3 VIKTORIA-2 trial to include endocrine-sensitive breast cancer patients. Trial expansion to endocrine-sensitive patients broadens potential market reach and approval prospects for Celcuity therapies.

Celcuity Inc. priced an upsized public offering of 0.250% Convertible Senior Notes due 2032. Convertible notes offering supplies Celcuity with fresh capital while increasing its convertible debt load.

Celcuity Inc. announces public offering of convertible senior notes due 2032. Convertible note offering supplies fresh capital while creating dilution risk and new debt obligations that moderately reshape financial position.

Celcuity’s Gedatolisib combination regimens doubled likelihood of survival without disease progression or death versus Alpelisib plus Fulvestrant in PIK3CA mutant cohort of pivotal Phase 3 VIKTORIA-1 trial in HR+/HER2- advanced breast cancer. Positive pivotal Phase 3 data for lead drug directly strengthens Celcuity's regulatory and commercial outlook.

Celcuity shares plunged to their worst day ever after disappointing late-stage breast cancer trial results triggered a massive selloff. Failed late-stage breast cancer trial results caused a record stock crash that will sharply impair Celcuity's development plans and investor outlook.

Celcuity reports gedatolisib outperformed Novartis' alpelisib plus fulvestrant in a Phase 3 trial. Positive Phase 3 data for gedatolisib signals major clinical and competitive advantage for Celcuity.

Celcuity breast cancer drug missed lofty expectations in ASCO-spotlighted trial. Trial miss for lead drug directly impairs Celcuity development timeline, regulatory path, and stock valuation.

Celcuity shares fell after release of strong Phase 3 breast cancer trial data. Strong Phase 3 breast cancer trial data positions Celcuity for regulatory approval and major revenue growth.

Celcuity shares crashed after its breast cancer treatment trial produced disappointing results. Breast cancer trial failure directly undermines Celcuity's lead pipeline asset and future revenue prospects.

Celcuity advances a new approach to breast cancer treatment with potential to drive major company growth. Novel breast cancer treatment approach signals major strategic progress likely to shift Celcuity's trajectory and sentiment.

Celcuity schedules conference call on June 2, 2026 to discuss results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 trial evaluating gedatolisib regimens in HR+/HER- advanced breast cancer. Phase 3 trial data readout for lead drug candidate can drive major shifts in company valuation and development path.

Celcuity reports positive VIKTORIA-1 trial data that supports higher valuation ahead of an imminent FDA decision on its lead therapy. Positive VIKTORIA-1 data plus an upcoming FDA decision create significant potential shifts in Celcuity's trajectory and investor sentiment.

Celcuity Inc (CELC) shared promising clinical trial progress and strategic updates during its Q1 2026 earnings call, highlighting advancements in its oncology drug development pipeline. Promising clinical trials and strategic initiatives represent major pipeline advancements poised to significantly enhance CELC's competitive position and investor sentiment.